Similarly, ORMD-0801 treatment elicited a sustained and highly significant reduction in mean nighttime, fasting, daytime and 24-h glucose concentrations.
← all excerpts
Report from the Scientific Poster Session at the 13th Annual Cardiometabolic Health Congress in Boston, USA, 24⁻27 October 2018.
1
—
—